Cover Image
Market Research Report

Real World Evidence (RWE) Solutions Market by Component (RWD, EMR, Claim, Patient Registry, Pharmacy, Service), Application (Oncology, CVD, Neuro, Infection, Regulatory), End User - Global Forecast to 2024

Published by Meticulous Market Research Pvt. Ltd. Product code 797391
Published Content info 166 Pages
Delivery time: 1-2 business days
Price
Back to Top
Real World Evidence (RWE) Solutions Market by Component (RWD, EMR, Claim, Patient Registry, Pharmacy, Service), Application (Oncology, CVD, Neuro, Infection, Regulatory), End User - Global Forecast to 2024
Published: February 1, 2019 Content info: 166 Pages
Description

Title:
Real World Evidence (RWE) Solutions Market
by Component (RWD, EMR, Claim, Patient Registry, Pharmacy, Service), Application (Oncology, CVD, Neuro, Infection, Regulatory), End User (Pharma, Biotech, Medical Devices, Payers, Healthcare) - Global Forecast to 2024.

The global Real-World Evidence (RWE) solutions market is expected to grow at a CAGR of 15.0% from 2019 to 2024 to reach $1.64 billion by 2024.

Traditional data collection is not sufficient for the success of drug or product development. With Randomized Controlled Trial (RCT), the results are obtained in a highly controlled environment, over a small set of patient population, over a short period of time, across a handful of highly dispersed clinical trial centers. Citing the potential of real-world data, the life science companies are focusing on evaluation of cost-efficiency of drugs in a real-world environment and measuring its impact on improving the quality of healthcare. Companies are recognizing that RCTs need to be supplemented or followed up with the comparatively new standard, called Real-World Evidence (RWE).

To meet the growing need of healthcare industry for more information on the real-life utilization of medicines and drug/device safety, there is a growing demand for real-world evidence which is dependent on patient data recorded by practitioners and administrators during routine course of care. These data are collected from various sources and are utilized for decision making, drug/device development, post-market monitoring, reducing costs, and improving care coordination.

Key Findings in the Real-World Evidence Solutions Market Study:

Data sets to witness largest share; whereas, services to register fastest growth

Data sets dominates the RWE market owing to increasing need for additional insights on epidemiology, compliance, adherence and costs in a realistic environment; growing amount of medical data generated in hospitals; increasing dependence of outcome-based studies on real-world data; and rising demand for information by the payers, regulatory bodies and providers regarding drug safety. However, RWE services are expected to witness fastest CAGR during the forecast period.

RWE finds major application in drug development & approvals

Drug development and approvals commanded the largest share 2018 owing to significant demand of RWD and RWE to accelerate drug discovery and development, increasing investment by biopharmaceutical companies in R&D, and growing inclination of regulatory bodies towards RWE. However, adoption of RWE for market access and reimbursement/coverage decisions is expected to witness fastest growth.

Pharmaceutical, biotechnology, and medical device companies are the leading adopters of RWE solutions

Pharmaceutical, biotech and medical device companies are the major end users of real-world evidence solutions market. This segment is also expected to register fastest CAGR primarily attributed to the increasing importance of RWE studies in drug development and approvals, growing focus to avoid costly drug recalls, increasing need to assess drug performance in real-world settings, and growing emphasis on drug safety and post-market surveillance.

North America comprises the largest share as well as fastest growth

North America commanded the largest share of the global real-world evidence solutions market in 2018, followed by Europe and Asia-Pacific. The largest share and fastest growth of this region is mainly attributed to significant availability of real-world data sets, growing focus on value-based care, rising R&D expenditure by the biopharma companies, greater emphasis on early drug/device development and approvals, presence of major RWE players in the region, stringent regulations for drug approvals, and supporting government policies (implementation of 21st Century Cures Act (December 2016) and FDA's new 2019 strategic Framework for RWE (December 2018) in the U.S).

Key Players:

The report includes competitive landscape based on extensive assessment of the key strategic developments adopted by leading market participants in the industry over the past 4 years (2015-2019). The key players profiled in the real-world evidence solutions market research report include Anthem, Inc., Clinigen Group plc, Cognizant, IBM Corporation, ICON plc, IQVIA, Optum,Inc., Oracle Corporation, PAREXEL International Corporation, PerkinElmer Inc., Pharmaceutical Product Development, LLC., SAS Institute Inc., and Syneos Health.

Scope of the Report:

Real-World Evidence Solutions Market, by Component

  • Data Sets
  • Disparate data sets
  • EMR/EHR/Clinical data
  • Pharmacy data
  • Product/disease registries
  • Claims & billing Data
  • Other data
  • Integrated data sets
  • Consulting/ Services

Real-World Evidence Solutions Market, by Application

  • Drug development & approvals
  • Oncology
  • Cardiovascular Disease
  • Neurology
  • Immunology
  • Other Therapeutic Areas
  • Market access &reimbursement/coverage decisions
  • Medical device development & approvals
  • Clinical decision-making
  • Other applications

Real-World Evidence Solutions Market, by End User

  • Pharmaceutical, biotechnology&medical device companies
  • Healthcare payers
  • Healthcare providers
  • Other Endusers

Real-World Evidence Solutions Market, by Geography

  • North America
    • U.S.A
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe (RoE)
  • Asia-Pacific (APAC)
    • China
    • Japan
    • Rest of APAC (RoAPAC)
  • Rest of the World
Table of Contents
Product Code: MRHC - 104253

Table of Contents

1. Introduction

  • 1.1. Market Definition
  • 1.2. Currency and Limitation
    • 1.2.1. Currency
    • 1.2.2. Limitations
  • 1.3. Key Stakeholders

2. Research Methodology

  • 2.1. Research Process
    • 2.1.1. Secondary Research
    • 2.1.2. Primary Research

3. Executive Summary

4. Market Insights

  • 4.1. Introduction
  • 4.2. Drivers
    • 4.2.1. Rising Geriatric Population and Burden of Chronic Diseases
    • 4.2.2. Shift Towards Value-Based Care
    • 4.2.3. Growing Focus on Personalized Health Care
    • 4.2.4. Delays in Drug Development and the Subsequent increase in Development Costs
    • 4.2.5. Expanding Use of RWE for Regulatory Decision Making
  • 4.3. Restraint
    • 4.3.1. Uneven Data Quality & Reluctance to Rely on Real-World Studies
  • 4.4. Opportunities
    • 4.4.1. Growth Opportunities in Emerging Markets
    • 4.4.2. Rising Focus on End-To-End RWE Services
    • 4.4.3. Emerging Roles of Wearable Devices and AI in RWE
  • 4.5. Challenge
    • 4.5.1. Lack of Standardized Methodologies to Develop RWE

5. Real-World Evidence Solutions Market, By Component

  • 5.1. Introduction
  • 5.2. Data Sets
    • 5.2.1. Disparate Data Sets
      • 5.2.1.1. EMR/EHR/Clinical Data
      • 5.2.1.2. Claims & Billing Data
      • 5.2.1.3. Pharmacy Data
      • 5.2.1.4. Product/Disease Registries Data
      • 5.2.1.5. Other Data
    • 5.2.2. Integrated Data Sets
  • 5.3. Consulting/ Services

6. Real-World Evidence Solutions Market, By Application

  • 6.1. Introduction
  • 6.2. Drug Development & Approvals, by Therapeutic Area
    • 6.2.1. Oncology
    • 6.2.2. Cardiovascular Diseases
    • 6.2.3. Neurology
    • 6.2.4. Immunology
    • 6.2.5. Other Therapeutic Areas
  • 6.3. Market Access & Reimbursement/Coverage Decisions
  • 6.4. Clinical Decision Making
  • 6.5. Medical Device Development & Approvals
  • 6.6. Others

7. Real-World Evidence Solutions Market, By End User

  • 7.1. Introduction
  • 7.2. Pharmaceutical, Biotechnology & Medical Device Companies
  • 7.3. Healthcare Payers
  • 7.4. Healthcare Providers
  • 7.5. Other End Users

8. Real-World Evidence Solutions Market, By Geography

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. U.S.
    • 8.2.2. Canada
  • 8.3. Europe
    • 8.3.1. U.K.
    • 8.3.2. Germany
    • 8.3.3. France
    • 8.3.4. Italy
    • 8.3.5. Spain
    • 8.3.6. Roe
  • 8.4. Asia-Pacific (APAC)
    • 8.4.1. Japan
    • 8.4.2. China
    • 8.4.3. RoAPAC
  • 8.5. Rest of the World (RoW)

9. Competitive Landscape

  • 9.1. Key Growth Strategies
  • 9.2. Competitive Benchmarking

10. Company Profiles

  • 10.1. Anthem, Inc.
    • 10.1.1. Business Overview
    • 10.1.2. Financial Overview
    • 10.1.3. Product Portfolio
    • 10.1.4. Strategic Developments
  • 10.2. Clinigen Group plc
    • 10.2.1. Business Overview
    • 10.2.2. Financial Overview
    • 10.2.3. Product Portfolio
    • 10.2.4. Strategic Developments
  • 10.3. Cognizant Technology Solutions (CTS) Corporation
    • 10.3.1. Business Overview
    • 10.3.2. Financial Overview
    • 10.3.3. Product Portfolio
    • 10.3.4. Strategic Developments
  • 10.4. IBM Corporation
    • 10.4.1. Business Overview
    • 10.4.2. Financial Overview
    • 10.4.3. Product Portfolio
    • 10.4.4. Strategic Developments
  • 10.5. ICON plc
    • 10.5.1. Business Overview
    • 10.5.2. Financial Overview
    • 10.5.3. Product Portfolio
    • 10.5.4. Strategic Developments
  • 10.6. IQVIA
    • 10.6.1. Business Overview
    • 10.6.2. Financial Overview
    • 10.6.3. Product Portfolio
    • 10.6.4. Strategic Developments
  • 10.7. Optum (A Subsidiary of United Health Group, Inc.)
    • 10.7.1. Business Overview
    • 10.7.2. Financial Overview
    • 10.7.3. Product Portfolio
    • 10.7.4. Strategic Developments
  • 10.8. Oracle Corporation
    • 10.8.1. Business Overview
    • 10.8.2. Financial Overview
    • 10.8.3. Product Portfolio
    • 10.8.4. Strategic Developments
  • 10.9. PAREXEL International Corporation
    • 10.9.1. Business Overview
    • 10.9.2. Financial Overview
    • 10.9.3. Product Portfolio
    • 10.9.4. Strategic Developments
  • 10.10. PerkinElmer Inc.
    • 10.10.1. Business Overview
    • 10.10.2. Financial Overview
    • 10.10.3. Product Portfolio
    • 10.10.4. Strategic Developments
  • 10.11. Pharmaceutical Product Development, LLC
    • 10.11.1. Business Overview
    • 10.11.2. Financial Overview
    • 10.11.3. Product Portfolio
    • 10.11.4. Strategic Developments
  • 10.12. SAS Institute Inc.
    • 10.12.1. Business Overview
    • 10.12.2. Financial Overview
    • 10.12.3. Product Portfolio
    • 10.12.4. Strategic Developments
  • 10.13. Syneos Health, Inc.
    • 10.13.1. Business Overview
    • 10.13.2. Financial Overview
    • 10.13.3. Product Portfolio
    • 10.13.4. Strategic Developments

11. Appendix

  • 11.1. Questionnaire
  • 11.2. Available Customization

List of Tables

  • Table 1: Global Real-World Evidence Solutions Market: Impact Analysis of Market Drivers (2019-2024)
  • Table 2: Global Real-World Evidence Solutions Market: Impact Analysis of Market Restraint (2019-2024)
  • Table 3: Global RWE Solutions Market Size, by Component, 2017-2024 ($Million)
  • Table 4: Global Data Sets Market Size, by Type, 2017-2024 ($Million)
  • Table 5: Global Data Sets Market Size, by Country/ Region, 2017-2024 ($Million)
  • Table 6: Global Disparate Data Sets Market Size, by Type, 2017-2024 ($Million)
  • Table 7: Global Disparate Data Sets Market Size, by Country/ Region, 2017-2024 ($Million)
  • Table 8: Global EMR/EHR/Clinical Data Sets Market Size For RWE, by Country/ Region, 2017-2024 ($Million)
  • Table 9: Global Claims & Billing Data Market Size For RWE, by Country/ Region, 2017-2024 ($Million)
  • Table 10: Global Pharmacy Data Market Size for RWE, By Country/ Region, 2017-2024 ($Million)
  • Table 11: Global Product/Disease Registries Market Size for RWE, By Country/ Region, 2017-2024 ($Million)
  • Table 12: Global Other Data Market Size For RWE, By Country/ Region, 2017-2024 ($Million)
  • Table 13: Global Integrated Data Sets Market Size For RWE, By Country/ Region, 2017-2024 ($Million)
  • Table 14: Global RWE Services Market Size, By Country/ Region, 2017-2024 ($Million)
  • Table 15: Global Real-World Evidence Solutions Market Size, by Application, 2017-2024 ($Million)
  • Table 16: Global RWE Solutions Market Size for Drug Development & Approvals, by Therapeutic Area, 2017-2024 ($ Million)
  • Table 17: Global RWE Solutions Market Size for Drug Development & Approvals, by Country/ Region, 2017-2024 ($Million)
  • Table 18: Global RWE Solutions Market Size for Oncological Drug Development & Approvals, by Country/ Region, 2017-2024 ($Million)
  • Table 19: Global RWE Solutions Market Size for Cardiovascular Drug Development & Approvals, by Country/ Region, 2017-2024 ($Million)
  • Table 20: Number of Drugs in Development for key Neurological Conditions
  • Table 21: Global RWE Solutions Market Size for Neurological Drug Development & Approvals, by Country/ Region, 2017-2024 ($Million)
  • Table 22: R&D Pipeline for Immunological Disorders
  • Table 23: Global RWE Solutions Market Size For Immunological Drug Development & Approvals, By Country/ Region, 2017-2024 ($Million)
  • Table 24: R&D Pipeline for Other Disorders
  • Table 25: Global RWE Solutions Market Size for other Drug Development & Approvals, by Country/ Region, 2017-2024 ($Million)
  • Table 26: Global RWE Solutions Market Size for Market Access & Reimbursement/ Coverage Decisions, by Country/ Region, 2017-2024 ($Million)
  • Table 27: Global RWE Solutions Market Size for Clinical Decision Making, by Country/ Region, 2017-2024 ($Million)
  • Table 28: Global RWE Solutions Market Size for Medical Device Development & Approvals, by Country/ Region, 2017-2024 ($Million)
  • Table 29: Global RWE Solutions Market Size for Other Applications, by Country/ Region, 2017-2024 ($Million)
  • Table 30: Global RWE Solutions Market Size, by End User, 2017-2024 ($Million)
  • Table 31: Global RWE Solutions Market Size for Pharmaceutical, Biotechnology & Medical Device Companies, by Country/ Region, 2017-2024 ($Million)
  • Table 32: Global RWE Solutions Market Size for Healthcare Payers, by Country/ Region, 2017-2024 ($Million)
  • Table 33: Global RWE Solutions Market Size for Healthcare Providers, by Country/ Region, 2017-2024 ($Million)
  • Table 34: Global RWE Solutions Market Size for Other End Users, by Country/ Region, 2017-2024 ($Million)
  • Table 35: Global Real-World Evidence Solutions Market Size, by Country, 2017-2024 ($Million)
  • Table 36: North America: RWE Solutions Market Size, by Country, 2017-2024 ($Million)
  • Table 37: North America: RWE Solutions Market Size, by Component, 2017-2024 ($Million)
  • Table 38: North America: Real-World Data Sets Market Size, by Type, 2017-2024 ($Million)
  • Table 39: North America: Disparate Data Sets Market Size, by Type, 2017-2024 ($Million)
  • Table 40: North America: RWE Solutions Market Size, by Application, 2017-2024 ($Million)
  • Table 41: North America: RWE Market Size For Drug Development & Approvals, by Therapeutic Type, 2017-2024 ($Million)
  • Table 42: North America: RWE Solutions Market Size, by End User, 2017-2024 ($Million)
  • Table 43: U.S.: RWE Solutions Market Size, by Component, 2017-2024 ($Million)
  • Table 44: U.S.: Real-World Data Sets Market Size, by Type, 2017-2024 ($Million)
  • Table 45: U.S.: Disparate Data Sets Market Size, by Type, 2017-2024 ($Million)
  • Table 46: U.S.: RWE Solutions Market Size, by Application, 2017-2024 ($Million)
  • Table 47: U.S.: RWE Market Size for Drug Development & Approvals, by Therapeutic Type, 2017-2024 ($Million)
  • Table 48: U.S.: RWE Solutions Market Size, by End User, 2017-2024 ($Million)
  • Table 49: Active Clinical Trials in Canada, 2018
  • Table 50: Canada: RWE Solutions Market Size, by Component, 2017-2024 ($Million)
  • Table 51: Canada: Real-World Data Sets Market Size, by Type, 2017-2024 ($Million)
  • Table 52: Canada: Disparate Data Sets Market Size, by Type, 2017-2024 ($Million)
  • Table 53: Canada: RWE Solutions Market Size, by Application, 2017-2024 ($Million)
  • Table 54: Canada: RWE Market Size For Drug Development & Approvals, by Therapeutic Type, 2017-2024 ($Million)
  • Table 55: Canada: RWE Solutions Market Size, by End User, 2017-2024 ($Million)
  • Table 56: Europe: RWE Solutions Market Size, by Country, 2017-2024 ($Million)
  • Table 57: Europe: RWE Solutions Market Size, by Component, 2017-2024 ($Million)
  • Table 58: Europe: Real-World Data Sets Market Size, by Type, 2017-2024 ($Million)
  • Table 59: Europe: Disparate Data Sets Market Size, by Type, 2017-2024 ($Million)
  • Table 60: Europe: RWE Solutions Market Size, by Application, 2017-2024 ($Million)
  • Table 61: Europe: RWE Solutions Market Size for Drug Development & Approvals, by Therapeutic Type, 2017-2024 ($Million)
  • Table 62: Europe: RWE Solutions Market Size, by End User, 2017-2024 ($Million)
  • Table 63: Adoption of Wearable Health Devices in U.K., 2015-17
  • Table 64: U.K.: Conferences and Workshops on Real-World Evidence Solutions
  • Table 65: U.K.: RWE Solutions Market Size, by Component, 2017-2024 ($Million)
  • Table 66: U.K.: Real-World Data Sets Market Size, by Type, 2017-2024 ($Million)
  • Table 67: U.K.: Disparate Data Sets Market Size, by Type, 2017-2024 ($Million)
  • Table 68: U.K.: RWE Solutions Market Size, by Application, 2017-2024 ($Million)
  • Table 69: U.K.: RWE Market Size for Drug Development & Approvals, by Therapeutic Type, 2017-2024 ($Million)
  • Table 70: U.K.: RWE Solutions Market Size, by End User, 2017-2024 ($Million)
  • Table 71: Germany: RWE Solutions Market Size, by Component, 2017-2024 ($Million)
  • Table 72: Germany: Real-World Data Sets Market Size, by Type, 2017-2024 ($Million)
  • Table 73: Germany: Disparate Data Sets Market Size, by Type, 2017-2024 ($Million)
  • Table 74: Germany: RWE Solutions Market Size, by Application, 2017-2024 ($Million)
  • Table 75: Germany: RWE Market Size For Drug Development & Approvals, by Therapeutic Type, 2017-2024 ($Million)
  • Table 76: Germany: RWE Solutions Market Size, by End User, 2017-2024 ($Million)
  • Table 77: France: RWE Solutions Market Size, by Component, 2017-2024 ($Million)
  • Table 78: France: Real-World Data Sets Market Size, by Type, 2017-2024 ($Million)
  • Table 79: France: Disparate Data Sets Market Size, by Type, 2017-2024 ($Million)
  • Table 80: France: RWE Solutions Market Size, by Application, 2017-2024 ($Million)
  • Table 81: France: RWE Market Size For Drug Development & Approvals, by Therapeutic Type, 2017-2024 ($Million)
  • Table 82: France: RWE Solutions Market Size, by End User, 2017-2024 ($Million)
  • Table 83: Italy: RWE Solutions Market Size, by Component, 2017-2024 ($Million)
  • Table 84: Italy: Real-World Data Sets Market Size, by Type, 2017-2024 ($Million)
  • Table 85: Italy: Disparate Data Sets Market Size, by Type, 2017-2024 ($Million)
  • Table 86: Italy: RWE Solutions Market Size, by Application, 2017-2024 ($Million)
  • Table 87: Italy: RWE Market Size For Drug Development & Approvals, by Therapeutic Type, 2017-2024 ($Million)
  • Table 88: Italy: RWE Solutions Market Size, by End User, 2017-2024 ($Million)
  • Table 89: Spain: RWE Solutions Market Size, by Component, 2017-2024 ($Million)
  • Table 90: Spain: Real-World Data Sets Market Size, by Type, 2017-2024 ($Million)
  • Table 91: Spain: Disparate Data Sets Market Size, by Type, 2017-2024 ($Million)
  • Table 92: Spain: RWE Solutions Market Size, by Application, 2017-2024 ($Million)
  • Table 93: Spain: RWE Market Size for Drug Development & Approvals, by Therapeutic Type, 2017-2024 ($Million)
  • Table 94: Spain: RWE Solutions Market Size, by End User, 2017-2024 ($Million)
  • Table 95: RoE: RWE Solutions Market Size, by Component, 2017-2024 ($Million)
  • Table 96: RoE: Real-World Data Sets Market Size, by Type, 2017-2024 ($Million)
  • Table 97: RoE: Disparate Data Sets Market Size, by Type, 2017-2024 ($Million)
  • Table 98: RoE: RWE Solutions Market Size, by Application, 2017-2024 ($Million)
  • Table 99: RoE: RWE Market Size for Drug Development & Approvals, by Therapeutic Type, 2017-2024 ($Million)
  • Table 100: RoE: RWE Solutions Market Size, by End User, 2017-2024 ($Million)
  • Table 101: APAC: RWE Solutions Market Size, by Country, 2017-2024 ($Million)
  • Table 102: APAC: RWE Market Size, by Component, 2017-2024 ($Million)
  • Table 103: APAC: Real-World Data Sets Market Size, by Type, 2017-2024 ($Million)
  • Table 104: APAC: Disparate Data Sets Market Size, by Type, 2017-2024 ($Million)
  • Table 105: APAC: RWE Solutions Market Size, by Application, 2017-2024 ($Million)
  • Table 106: APAC: RWE Market Size for Drug Development & Approvals, by Therapeutic Type, 2017-2024 ($Million)
  • Table 107: APAC: RWE Solutions Market Size, by End User, 2017-2024 ($Million)
  • Table 108: Japan: RWE Solutions Market Size, by Component, 2017-2024 ($Million)
  • Table 109: Japan: Real-World Data Sets Market Size, by Type, 2017-2024 ($Million)
  • Table 110: Japan: Disparate Data Sets Market Size, by Type, 2017-2024 ($Million)
  • Table 111: Japan: RWE Solutions Market Size, by Application, 2017-2024 ($Million)
  • Table 112: Japan: RWE Market Size for Drug Development & Approvals, by Therapeutic Type, 2017-2024 ($Million)
  • Table 113: Japan: RWE Solutions Market Size, by End User, 2017-2024 ($Million)
  • Table 114: China: RWE Solutions Market Size, by Component, 2017-2024 ($Million)
  • Table 115: China: Real-World Data Sets Market Size, by Type, 2017-2024 ($Million)
  • Table 116: China: Disparate Data Sets Market Size, by Type, 2017-2024 ($Million)
  • Table 117: China: RWE Solutions Market Size, by Application, 2017-2024 ($Million)
  • Table 118: China: RWE Market Size for Drug Development & Approvals, by Therapeutic Type, 2017-2024 ($Million)
  • Table 119: China: RWE Solutions Market Size, by End User, 2017-2024 ($Million)
  • Table 120: Real-World Evidence Related Conferences Held in RoAPAC Region, 2017-18
  • Table 121: RoAPAC: RWE Solutions Market Size, by Component, 2017-2024 ($Million)
  • Table 122: RoAPAC: Real-World Data Sets Market Size, by Type, 2017-2024 ($Million)
  • Table 123: RoAPAC: Disparate Data Sets Market Size, by Type, 2017-2024 ($Million)
  • Table 124: RoAPAC: RWE Solutions Market, by Application, 2017-2024 ($Million)
  • Table 125: RoAPAC: RWE Market Size For Drug Development & Approvals, by Therapeutic Type, 2017-2024 ($Million)
  • Table 126: RoAPAC: RWE Solutions Market Size, by End User, 2017-2024 ($Million)
  • Table 127: RoW: RWE Solutions Market Size, by Component, 2017-2024 ($Million)
  • Table 128: RoW: Real-World Data Sets Market Size, by Type, 2017-2024 ($Million)
  • Table 129: RoW: Disparate Data Sets Market Size, by Type, 2017-2024 ($Million)
  • Table 130: RoW: RWE Solutions Market Size, by Application, 2017-2024 ($Million)
  • Table 131: RoW: RWE Market Size For Drug Development & Approvals, by Therapeutic Type, 2017-2024 ($Million)
  • Table 132: RoW: RWE Solutions Market Size, by End User, 2017-2024 ($Million)
  • Table 133: Number Of Developments Made by The Profiled Companies, January 2015-January 2019
  • Table 134: Key Products: Real-World Evidence Solutions

List of Figures

  • Figure 1: Market Ecosystem
  • Figure 2: Key Stakeholders of Real-World Evidence Solutions Market
  • Figure 3: Research Process
  • Figure 4: Key Executives Interviewed
  • Figure 5: Primary Research Techniques
  • Figure 6: Market Size Estimation
  • Figure 7: Key Opportunities
  • Figure 8: Scope of Real-World Evidence Solutions Market
  • Figure 9: Real-World Evidence Solutions Market, by Component
  • Figure 10: Real-World Evidence Solutions Market, by Application
  • Figure 11: Real-World Evidence Solutions Market, by End User
  • Figure 12: Key Adopters
  • Figure 13: Market Dynamics
  • Figure 14: Percentage Distribution of Population Aged 65 Years & Above, by Region, 2015-2050
  • Figure 15: Increasing Number of People with Chronic Conditions
  • Figure 16: Key Findings on Drug Development
  • Figure 17: Global Real-World Evidence Solutions Market, By Component, 2019-2024 ($Million)
  • Figure 18: U.S.: Key Findings of EHR
  • Figure 19: Use of E-Prescription in U.S., 2017
  • Figure 20: Percentage of Specialists Using E-Prescriptions in the U.S., 2017
  • Figure 21: Real World Evidence Solutions Market, by Application, 2019-2024 ($Million)
  • Figure 22: Global Cancer Incidence and Mortality, 2018
  • Figure 23: Key Findings of Alzheimer's and other Dementias in the U.S.
  • Figure 24: Global RWE Solutions Market Size, by End User, 2019-2024 ($Million)
  • Figure 25: Pharmaceutical R&D Spending, 2010-2015
  • Figure 26: Global Real-World Evidence Solutions Market Size, by Region, 2019-2024 ($Million)
  • Figure 27: Percentage of Office-Based Physicians with Electronic Health Record System in U.S., 2010-2015
  • Figure 28: Annual Novel Drug Approvals by CDER, 2010 - 2017
  • Figure 29: Real-World Evidence Conferences Held in U.S., 2018
  • Figure 30: Key Findings of Cancer in Canada, 2017
  • Figure 31: Total Project Breakdown by Therapeutic Area, 2017-18
  • Figure 32: Pharmaceutical Industry R&D Expenditure in European Countries, 2014
  • Figure 33: Pharmaceutical R&D Expenditure in Italy
  • Figure 34: Pharmaceutical R&D in Spain, 2015-16
  • Figure 35: Number of People >65 Years of Age in Japan, 2000-2050
  • Figure 36: Investigator Initiated Clinical Trials in Japan
  • Figure 37: Key Growth Strategies Adopted by Leading Players During January 2015-January 2019
  • Figure 38: Real-World Evidence Solutions Market: Competitive Benchmarking
  • Figure 39: Anthem, Inc.: Financial Overview (2015-2017)
  • Figure 40: Clinigen Group Plc: Financial Overview (2016-2018)
Back to Top